Research programme: autologous stem cell therapies - GWOXI

Drug Profile

Research programme: autologous stem cell therapies - GWOXI

Alternative Names: Autologous adipose-derived stem cells - GWOXI; GXNPC1; hADSC - GWOXI; human adipose-derived stem cells - GWOXI

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator GWOXI Stem Cell Applied Technology
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Stroke

Most Recent Events

  • 22 Jun 2016 GWOXI Stem Cell Applied Technology plans a phase I trial in Stroke in Taiwan (NCT02813512)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top